Vaxxas’ needle-free seasonal influenza vaccine enters clinical trial
AU Manufacturing
FEBRUARY 11, 2023
Vaxxas , a biotechnology company commercialising a novel vaccination platform, has commenced the Phase I clinical trial of the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate via its proprietary high-density microarray patch (HD-MAP) technology.
Let's personalize your content